[Form 4] ResMed Inc. Insider Trading Activity

Rhea-AI Filing Summary

Filing: Form 4 filed by Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), signed 08/04/2025.

On 08/01/2025 Mr. Sandercock reported two non-derivative transactions and one derivative entry. He acquired 2,000 shares of ResMed common stock under a Rule 10b5-1 plan at $101.64 (reported beneficial ownership after this line: 86,283 shares). He disposed of 3,000 shares at $281.90 (reported beneficial ownership after this line: 83,283 shares). Separately, he reported 2,000 option-related derivative securities with an exercise price of $101.64, exercisable from 11/11/2019 and expiring 11/14/2025, leaving 6,000 derivative securities beneficially owned following the report.

Disclosures: The stock transactions were executed under a Rule 10b5-1 plan adopted February 19, 2025. Options vest 1/3 per year.

Positive

• 2,000 shares acquired under a Rule 10b5-1 plan at $101.64 (transaction dated 08/01/2025)
• Rule 10b5-1 plan in place (adopted February 19, 2025), indicating use of a documented trading plan
• Timely disclosure with Form 4 signed 08/04/2025

Negative

• 3,000 shares sold at $281.90 on 08/01/2025 (reported on Form 4)
• Options expire soon (expiration date 11/14/2025), which may prompt near-term decisions regarding exercise or disposition

Insights

Financial Analyst

TL;DR Mixed insider activity: simultaneous planned purchase and sale plus outstanding options; net investor impact appears neutral from the filing alone.

This Form 4 records contemporaneous planned purchase (2,000 shares at $101.64) and sale (3,000 shares at $281.90) by the CFO under a Rule 10b5-1 plan adopted February 19, 2025. The report also documents 2,000 derivative securities with an exercise price of $101.64 exercisable since 11/11/2019 and expiring 11/14/2025, with 6,000 options held after the transactions. For investors, these are factual disclosures of insider trading and equity-based compensation activity; the filing does not state intent or rationale, and no additional corporate financial metrics are provided.

Corporate Governance Expert

TL;DR Compliance-focused filing: transactions executed under a 10b5-1 plan and disclosed promptly; governance implications are procedural, not corrective.

The filing documents the CFO's transactions performed under a Rule 10b5-1 plan (adopted 02/19/2025), which demonstrates use of an affirmative defense for scheduled trades. The form includes required detail: transaction dates (08/01/2025), prices ($101.64 purchase, $281.90 sale), quantities (2,000 bought, 3,000 sold), and option exercise terms (exercise price $101.64; exercisable 11/11/2019; expires 11/14/2025). From a governance standpoint, the filing meets Section 16 disclosure obligations; it contains no admission of wrongdoing or material corporate changes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandercock Brett

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	08/01/2025		M(1)		2,000	A	$101.64	86,283	D
ResMed Common Stock	08/01/2025		S(1)		3,000	D	$281.9	83,283	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$101.64	08/01/2025		M(1)			2,000	11/11/2019(2)	11/14/2025	ResMed Common Stock	2,000	$0	6,000	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

2. Represents date options first become exercisable. Options vest 1/3 per year.

	Brett Sandercock, Chief Financial Officer	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ResMed CFO Brett Sandercock report on Form 4 (RMD)?

The Form 4 reports that Brett Sandercock acquired 2,000 shares at $101.64 and disposed of 3,000 shares at $281.90 on 08/01/2025, and reported derivative holdings.

Were the transactions executed under a trading plan for RMD?

Yes. The filing states the transactions were conducted under a Rule 10b5-1 plan adopted February 19, 2025.

How many derivative securities did the CFO report and what are the key terms?

The report shows 2,000 derivative securities with an exercise price of $101.64, exercisable from 11/11/2019 and expiring 11/14/2025, leaving 6,000 total derivative securities beneficially owned after the transactions.

What beneficial ownership totals are reported after the transactions?

The filing lists beneficial ownership following the acquisition line as 86,283 shares and following the disposition line as 83,283 shares (each line reported separately).

When was the Form 4 signed and filed?

The filing is signed by Brett Sandercock on 08/04/2025.